liver codon optimization (lco) algorithm (GenScript corporation)
90
Structured Review
GenScript corporation
liver codon optimization (lco) algorithm
![AAV-AnFIX gene therapy. (A) AAV vectors incorporating AAV2 inverted terminal repeats, either the HCB (146 nt) or HHS4 (294 nt) promoter, a minute virus of mice (MVM) intron (92 nt), a FIX transgene, and a synthetic β-globin polyadenylation signal are depicted. The predicted HCB- and HHS4-containing ssDNA AAV genome sizes are 2003 and 2151 nt, respectively. (B) Hemophilia B mice were injected IV with 5 × 1012 vg/kg AAV2/8 encoding An96 <t>Padua-LCO</t> (closed circles) or hFIX-Padua (open triangles) driven by the highly compact, liver-directed HCB promoter (n = 6 per group). Plasma was collected biweekly for 12 weeks, and FIX activity was determined by 1-stage clotting assay. (C) Hemophilia B mice were injected IV with a 37-fold lower dose (1.4 × 1011 vp/kg) of AAV2/8-HHS4-An96-Padua (closed circles), AAV2/8-HHS4-An96 (closed squares), or AAV2/8-HHS4-hFIX-Padua (open triangles; n = 4-6 per group). Plasma was collected biweekly for 12 weeks, and FIX activity was determined by 1-stage clotting assay (C) or chromogenic assay (Rox Factor IX; Diapharma, West Chester, OH) (D). (E) AAV vector copy number was determined from liver tissue <t>genomic</t> <t>DNA</t> using qPCR. No significant differences were observed among the groups (1-way analysis of variance [ANOVA]; P = .2). (F) Saphenous vein bleeding challenge was performed on mice from each group (from left to right, open diamonds represent wild-type C57Bl/6; closed diamonds, untreated hemophilia B; open triangles, hFIX-Padua transgene; closed circles, An96-Padua transgene; closed squares, An96 transgene). The average time to clot for each mouse was measured over 30 minutes. Comparisons among the groups were made by 1-way ANOVA and post hoc Holm-Sidak testing. All groups were significantly different to the untreated hemophilia B (negative control) group (P < .05). (G) Dose-response curves were generated by administration of log10 doses of AAV2/8-HHS4-An96-Padua at 1.4 × 109 (circles), 1.4 × 1010 (squares), or 1.4 × 1011 vp/kg (triangles) to hemophilia B mice (n = 5-7 per group). Plasma FIX activity was measured by 1-stage clotting assay at biweekly intervals.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_5220/pmc08525220/pmc08525220__advancesADV2021004742f4.jpg)
Liver Codon Optimization (Lco) Algorithm, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+optimization+algorithm/pmc08525220-59-27-39?v=GenScript+corporation
Average 90 stars, based on 1 article reviews
Liver Codon Optimization (Lco) Algorithm, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+optimization+algorithm/pmc08525220-59-27-39?v=GenScript+corporation
Average 90 stars, based on 1 article reviews
liver codon optimization (lco) algorithm - by Bioz Stars,
2026-07
90/100 stars
Images
1) Product Images from "Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction"
Article Title: Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction
Journal: Blood Advances
doi: 10.1182/bloodadvances.2021004742
Figure Legend Snippet: AAV-AnFIX gene therapy. (A) AAV vectors incorporating AAV2 inverted terminal repeats, either the HCB (146 nt) or HHS4 (294 nt) promoter, a minute virus of mice (MVM) intron (92 nt), a FIX transgene, and a synthetic β-globin polyadenylation signal are depicted. The predicted HCB- and HHS4-containing ssDNA AAV genome sizes are 2003 and 2151 nt, respectively. (B) Hemophilia B mice were injected IV with 5 × 1012 vg/kg AAV2/8 encoding An96 Padua-LCO (closed circles) or hFIX-Padua (open triangles) driven by the highly compact, liver-directed HCB promoter (n = 6 per group). Plasma was collected biweekly for 12 weeks, and FIX activity was determined by 1-stage clotting assay. (C) Hemophilia B mice were injected IV with a 37-fold lower dose (1.4 × 1011 vp/kg) of AAV2/8-HHS4-An96-Padua (closed circles), AAV2/8-HHS4-An96 (closed squares), or AAV2/8-HHS4-hFIX-Padua (open triangles; n = 4-6 per group). Plasma was collected biweekly for 12 weeks, and FIX activity was determined by 1-stage clotting assay (C) or chromogenic assay (Rox Factor IX; Diapharma, West Chester, OH) (D). (E) AAV vector copy number was determined from liver tissue genomic DNA using qPCR. No significant differences were observed among the groups (1-way analysis of variance [ANOVA]; P = .2). (F) Saphenous vein bleeding challenge was performed on mice from each group (from left to right, open diamonds represent wild-type C57Bl/6; closed diamonds, untreated hemophilia B; open triangles, hFIX-Padua transgene; closed circles, An96-Padua transgene; closed squares, An96 transgene). The average time to clot for each mouse was measured over 30 minutes. Comparisons among the groups were made by 1-way ANOVA and post hoc Holm-Sidak testing. All groups were significantly different to the untreated hemophilia B (negative control) group (P < .05). (G) Dose-response curves were generated by administration of log10 doses of AAV2/8-HHS4-An96-Padua at 1.4 × 109 (circles), 1.4 × 1010 (squares), or 1.4 × 1011 vp/kg (triangles) to hemophilia B mice (n = 5-7 per group). Plasma FIX activity was measured by 1-stage clotting assay at biweekly intervals.
Techniques Used: Virus, Injection, Clinical Proteomics, Activity Assay, Coagulation, Chromogenic Assay, Plasmid Preparation, Negative Control, Generated
